Effects of Psychotropic Drugs on Weight
1999; Slack Incorporated (United States); Volume: 29; Issue: 10 Linguagem: Inglês
10.3928/0048-5713-19991001-08
ISSN1938-2456
AutoresNorman Sussman, David Ginsberg,
Tópico(s)Pharmacology and Obesity Treatment
ResumoManagement of the Side Effects of Psychotropic DrugsEffects of Psychotropic Drugs on Weight Norman Sussman, MD, , and , MD David Ginsberg, MD, , MD Norman Sussman, MD and David Ginsberg, MD Psychiatric Annals, 2013;29(10):580–594Published Online:October 01, 1999https://doi.org/10.3928/0048-5713-19991001-08Cited by:23View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998; 105:145-150. Google Scholar2. Huether G, Zhou D, Schmidt S, Wiltfang J, Ruther. Longterm food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry. 1997;41:1174-1180. Google Scholar3. Jahng TW, Houpt TA, Kim SJ, Jon TH, Son JH. Neuropeptide Y mRNA and serotonin innervation in the arcuate nucleus of anorexia mutant mice. Brain Res. 1998;790:67-73. Google Scholar4. Dryden S, Frankish HM, Wang Q, Pickarence L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience. 1996;72:557566. Google Scholar5. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopiutrmacol Bull 1988;24:220-223. Google Scholar6. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141-145. Google Scholar7. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol. 1993;13(suppl 2): 18S-22S. Google Scholar8. Darga LL, Carol-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54:321-325. Google Scholar9. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176. Google Scholar10. Mackle M, Kocsis J. Effects on body weight of the SSRI Citalopram. Presented at the annual meeting of the American College of Neuropharmacology; December 1998. Google Scholar11. Fogelson DL. Weight gain during fluoxetine treatment. J Clin Psychopharmacol. 1991;11:220-221. Google Scholar12. Bou wer CD, Harvey BH. Phasic craving for carbohydrate observed with Citalopram. Int Clin Psychopharmacol. 1996;11:273-278. Google Scholar13. Agren H Aberg-Wistedt A, Akerblad A-C. NR366 sertraline versus paroxetine in major depression: a multicentre double-blind, 24-week comparison. Presented at the annual meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998. Google Scholar14. Fava M, Rosenbaum JF. Treatment-emergent side effects of the newer antidepressants. In: Jefferson JW, Greist JH, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1996. Philadelphia: W. B. Saunders; 1996:13-29. Google Scholar15. Joubert AF, Gagiano CA, Joubert G. Antidepressants and weight: comparative study of four antidepressants and their effect on weight. Eur Ncuropsychopharmacol. 1996;6(suppl 3):143. Google Scholar16. Amsterdam JD, Garcia-Espana F, Goodman D, Hooper MB, Hornig-Rohan M. Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997;46:151-156. Google Scholar17. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1995;56:288-296. Google Scholar18. Feighner JP, Gardner EA, Johnston JA, Batey SR. Doubleblind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52:329-335. Google Scholar19. Goodnick PJ, Kremer C, Wingard P. Weight change during mirtazapine therapy, Primary Psychiatry. 1998:103-108. Google Scholar20. Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. CNS Drugs. 1998;9:135-151. Google Scholar21. Martinez JA, Velasco JJ, Urbistondo MD. Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J Am Coll Nutr. 1994;13:192-197. Google Scholar22. Allison DB, Mentore JL, Heo M, et al. Weight gain associated with conventional and newer antipsychotics: a metaanalysis. Presented at the 21st Annual Collegium Internationale Neuro-Psychopharmacologicum Congress; Glasgow, Scotland; July 13-16, 1998. Google Scholar23. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull. 1995;21:463-472. Google Scholar24. Doss FW. The effect of antipsychotic drugs on bodyweight: a retrospective review. J Clin Psychiatry. 1979;40:528-530. Google Scholar25. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992;149:689-690. Google Scholar26. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapineinduced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149:68-72. Google Scholar27. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry. 1994;55(9 suppl B):157-160. Google Scholar28. Bustillo JR, Buchanan RW, Irish D, et al. Differential effects of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153:817-819. Google Scholar29. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy. 1995;15:382. Abstract. Google Scholar30. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079-2081. Google Scholar31. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998;21:245-250. Google Scholar32. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156:1270-1272. Google Scholar33. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(suppl 11):53-60. Google Scholar34. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58(suppl 10):13-17. Google Scholar35. Osser DN, Najarian D, Berman I, et al. Olanzapine increases weight and triglyceride levels. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998. Google Scholar36. Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156:1471-1472. Letter. Google Scholar37. Amery W, Zuiderwijk P, Brecher M, et al. Safety profile of risperidone. Presented at the Thirty-Sixth Annual Meeting of the American College of Neuropsychopharmacology; Kamuela, Hawaii; December 8-12, 1997. Google Scholar38. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic controL Clin Drug Invest. 1999;19:99-104. Google Scholar39. Chou JCY, Serper MR. Ziprasidone: a new highly atypical antipsychotic. For Essential Psychopharmacology. 1998; 2:463-185. Google Scholar40. Ganguli R, Brar JS, Ayrton Z. Weight gain with atypical antipsychotic medications. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998. Google Scholar41. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312-314. Google Scholar42. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363. Google Scholar43. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry. 1994;151:1395. Letter. Google Scholar44. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry. 1994;151:1520-1521. Letter. Google Scholar45. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J din Psychiatry. 1997;58:108-111. Google Scholar46. Hagg S, Joelsson J, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299. Google Scholar47. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778-783. Google Scholar48. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine. J CUn Psychiatry. 1998;59:687698. Letter. Google Scholar49. Lindenmayer JP, Patel R. Olanzapine-induces ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999;156:1471. Letter. Google Scholar50. Sobel M, Jaggers ED, Frantz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry. 1999;60:556-557. Letter. Google Scholar51. Zoler ML. Antipsychotics linked to weight gain, diabetes. Clinical Psychiatry Nexos. 1999;27:20. Google Scholar52. Keskiner A, El Toumi A, Bousquet T. Psychotropic drugs, diabetes, and chronic mental patients. PsychosomaHcs. 1973;14:176-181. Google Scholar53. Schwartz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry. 1968;125:253-255. Google Scholar54. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci. 1991;49:101-109. Google Scholar55. Uvnas-Moberg K, Ahlenius S, Alster P, et al. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagon in the rat. Neuroendocrinology. 1996;63:269-274. Abstract. Google Scholar56. Chaouloff F, Laude D, Baudrie V. Effects of the 5-HT1CJ55-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol. 1990;187:435-443. Google Scholar57. Yamada J, Sugimoto Y, Yoshikawa T, et al. The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycemia in rats. Life Sci. 1995;57:819-825. Abstract. Google Scholar58. Kerry FJ, Liebling LI, Owen G. Weight changes in lithium responders. Acta Psychiatr Scand. 1970;46:238-243. Google Scholar59. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol. 1990;5:217-225. Google Scholar60. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort: 3. Tremor, weight gain, psychological complaints. Acta Psychiatr Scand. 1988;78:434-441. Google Scholar61. Vendsborg PB, Bech P, Rafaelson OJ. Lithium treatment and weight gain. Acta Psychiatr Scand. 1976;53:139-147. Google Scholar62. Mellerup ET, Plenge PK, Rafaelson OJ. Lithium and insulin effects on carbohydrate and electrolyte metabolism. Dan Med Bull. 1974;21:88-91. Google Scholar63. Batiacharya G. Influence of lithium on glucose metabolism in rats and rabbits. Biochem Biophys Acta. 1964;93:644646. Google Scholar64. Clausen T. The relationship between the transport of glucose and cations across cell membranes in isolated tissues: rv. The "insulin-like" effect of lithium. Biochem Biophys Acta. 1968;150:66-72. Google Scholar65. Birnbaum L, Pohl SL, Rodbell M. Adenyl cyclase in fat cells. J Biol Chem. 1969;244:3468-3476. Google Scholar66. Krulic R, Janko L, Cerny M. Metabolism of lipids in lithium-administered rats. Acta Univ Carol [Med] (Praha). 1971;17:533-540. Google Scholar67. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ. 1981;283:577581. Google Scholar68. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand. 1984,69:6569. Google Scholar69. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open label study. Headache. 1991;31:71-74. Google Scholar70. Sharpe C, Buchanan N. Juvenile myoclonic epilepsy: diagnosis, management, and outcome. Med J Aust. 1995;162:133-134. Google Scholar71. Dulac O, Stem D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev. 1986;8:4752. Google Scholar72. Davis R, Peters DH McTavish D. Valproic add: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332-372. Google Scholar73. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: relation to obesity. Epilepsy Res. 1993;16:55-64. Google Scholar74. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism. 1992;41:666-670. Google Scholar75. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383-1388. Google Scholar76. Sussman N, Ginsberg D. Valproate and risk of polycystic ovary syndrome. Primary Psychiatry. 1998;5:42-48. Google Scholar77. Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry. 1986;47:313-314. Google Scholar78. Lampi Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol. 1991;14:251-255. Google Scholar79. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonicclonic seizures in adults. N Engl J Med. 1992;327:765-771. Google Scholar80. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry. 1994;57:682-687. Google Scholar81. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995;37:97-108. Google Scholar82. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry. 1995;152:1399. Letter. Google Scholar83. Mellick GA, Mellicy LB, Mellick JD. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage. 1995;10:265-266. Google Scholar84. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998,43:305. Letter. Google Scholar85. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155:992-993. Letter. Google Scholar86. Markowitz JS, Finkenbine R, Myrick H, et al, Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol 1997;17:423-424. Google Scholar87. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632. Letter. Google Scholar88. Gidal BE, MaIy MM, Nemire RE, et al. Weight gain and gabapentin therapy. Ann Pharmacother. 1995;29:1048. Letter. Google Scholar89. DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19:394-396. Google Scholar90. Baulac M, Cavalcanti F, Semah F, et al. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. Seizure. 1998;7:55-62. Google Scholar91. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry. 1996;153:1236. Google Scholar92. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res. 1997;72:145-148. Google Scholar93. Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: treatment options. Can J Psychiatry. 1997;42 (suppl 2):87S-91S. Google Scholar94. Leach MJ, Baxter MG, Critchley MAE. Neurochemical and behavioural aspects of lamotrigine. Epilepsia. 1991;32:S4-S8. Google Scholar95. Southern E, Kirkby D, Higgins GA, et al. Lamotrigine inhibits monoamine uptake in vitro and modulates 5hydroxytryptamine uptake in rats. Eur J Pharmacol 1998;358:19-24. Google Scholar96. Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine. Epilepsia. 1991;32(suppl 2):S17-S21. Google Scholar97. Isojarvi JTT, Rattya J, Myllyla W, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43:446-451. Google Scholar98. Montouris G, Mirza WU, Biton V, et al. Effects of lamictal and depakote monotherapy on body weight in patients with epilepsy: interim analysis of a randomized, doubleblind clinical trial. Presented at the 51st Annual Meeting of the American Academy of Neurology; Toronto, Ontario, Canada; April 17-24, 1999. Google Scholar99. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm. 1998;55:554-562. Google Scholar100. Marcotte DB. Use of the new antiepileptic drug topiramate as a mood stabilizer. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998. Google Scholar101. Calabrese JR, Shelton MD, Keck PE, et al. Emerging trends in the management of psychiatric illness. Presented at the Annual Meeting of the American Psychiatric Association; Toronto, OntarioJ Canada; May 30-June 4, 1998. Google Scholar102. Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia. 1997;38(suppl 3):58. Google Scholar103. Norton J, Potter D, Edwards K. Sustained weight loss with topiramate. Epilepsia. 1997;38suppl 3):60. Google Scholar104. Lichter PR. Reducing side effects of carbonic anhydrase inhibitors. Ophthalmology. 198138:266-269. Google Scholar105. Meyer JS, Gotoh F, Tazoki Y Inhibitory action of carbon dioxide and acetazolamide in seizure activity electroencephalography. Clin Neurophysiol 1961;13:762-775. Google Scholar106. United States Pharmacoepia Drug Information (USP-DI). Carbonic Anhydrase Inhibitors (Systemic). Taunton, MA: Micromedex; 1998:729. Google Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Gowey M, Reiter-Purtill J, Becnel J, Peugh J, Mitchell J and Zeller M (2016) Weight-related correlates of psychological dysregulation in adolescent and young adult (AYA) females with severe obesity, Appetite, 10.1016/j.appet.2016.01.020, 99, (211-218), Online publication date: 1-Apr-2016. (2016) Lithium Meyler's Side Effects of Drugs, 10.1016/B978-0-444-53717-1.00985-9, (597-660), . Abbas M and Liddle P (2012) Olanzapine and food craving: a case control study, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2278, 28:1, (97-101), Online publication date: 1-Jan-2013. (2009) ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS Meyler's Side Effects of Endocrine and Metabolic Drugs, 10.1016/B978-0-444-53271-8.50011-9, (571-691), . (2009) ANTIDEPRESSANTS Meyler's Side Effects of Psychiatric Drugs, 10.1016/B978-0-444-53266-4.50004-5, (1-184), . Milano W, Grillo F, Del Mastro A, De Rosa M, Sanseverino B, Petrella C and Capasso A (2007) Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study, Advances in Therapy, 10.1007/BF02850000, 24:1, (123-134), Online publication date: 1-Jan-2007. Gentile S (2006) Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain, Drug Safety, 10.2165/00002018-200629040-00002, 29:4, (303-319), . (2006) Lithium Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 10.1016/B0-44-451005-2/00079-6, (2073-2116), . Virk S, Schwartz T, Jindal S, Nihalani N and Jones N (2004) Psychiatric medication induced obesity: an aetiologic review, Obesity Reviews, 10.1111/j.1467-789X.2004.00141.x, 5:3, (167-170), Online publication date: 1-Aug-2004. Schwartz T, Nihalani N, Jindal S, Virk S and Jones N (2004) Psychiatric medication-induced obesity: a review, Obesity Reviews, 10.1111/j.1467-789X.2004.00139.x, 5:2, (115-121), Online publication date: 1-May-2004. Ozcan M, Kaya B and Polat R (2004) Weight gain and improvement with quetiapine in bipolar I disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/j.pnpbp.2003.11.001, 28:2, (413-415), Online publication date: 1-Mar-2004. Pouzet B, Mow T, Kreilgård M and Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human, Pharmacology Biochemistry and Behavior, 10.1016/S0091-3057(03)00042-X, 75:1, (133-140), Online publication date: 1-Apr-2003. Nasrallah H (2003) A review of the effect of atypical antipsychotics on weight, Psychoneuroendocrinology, 10.1016/S0306-4530(02)00114-2, 28, (83-96), Online publication date: 1-Jan-2003. Guille C and Sachs G (2002) Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/S0278-5846(01)00278-0, 26:6, (1035-1039), Online publication date: 1-Oct-2002. &NA; (2002) Atypical antipsychotics and bodyweight gain: how serious is the problem?, Drugs & Therapy Perspectives, 10.2165/00042310-200218080-00008, 18:8, (23-26), Online publication date: 1-Aug-2002. Mavissakalian M, Perel J and Guo S (2002) Specific Side Effects of Long-Term Imipramine Management of Panic Disorder, Journal of Clinical Psychopharmacology, 10.1097/00004714-200204000-00008, 22:2, (155-161), Online publication date: 1-Apr-2002. Richelson E (2001) Pharmacology of antidepressants, Mayo Clinic Proceedings, 10.4065/76.5.511, 76:5, (511-527), Online publication date: 1-May-2001. Russell J and Mackell J (2001) Bodyweight Gain Associated with Atypical Antipsychotics, CNS Drugs, 10.2165/00023210-200115070-00004, 15:7, (537-551), . Barnes T and Joyce E (2001) Antipsychotic drug treatment: recent advances, Current Opinion in Psychiatry, 10.1097/00001504-200101000-00005, 14:1, (25-37), Online publication date: 1-Jan-2001. Jefferson J (2001) Lithium , 10.1016/S0378-6080(01)80008-8, (22-31), . Keltner N, Coffeen H and Johnson J (2009) Biological Perspectives, Perspectives in Psychiatric Care, 10.1111/j.1744-6163.2000.tb00603.x, 36:4, (139-141) Green A, Patel J, Goisman R, Allison D and Blackburn G (2000) Weight gain from novel antipsychotic drugs: need for action, General Hospital Psychiatry, 10.1016/S0163-8343(00)00081-5, 22:4, (224-235), Online publication date: 1-Jul-2000. Sajatovic M, Madhusoodanan S and Buckley P (2000) Schizophrenia in the Elderly, CNS Drugs, 10.2165/00023210-200013020-00004, 13:2, (103-115), Online publication date: 1-Feb-2000. Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 28.5 MB Published online10/01/99
Referência(s)